The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10241 malaria professionals are enjoying the free benefits of MalariaWorld today

anti-malarial drugs

Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs

February 2, 2016 - 19:08 -- Open Access
Tags: 
Author(s): 
Samuel Ayodele Egieyeh, James Syce, Sarel F. Malan and Alan Christoffels
Reference: 
Malaria Journal 2016 15:50, 29 January 2016

Chemo-informatic profiling of NAA and CRAD have produced a wealth of information that may guide decisions and facilitate anti-malarial drug development from natural products.

Medical Treatment: 

NOT Open Access | Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection

January 26, 2016 - 18:55 -- NOT Open Access
Tags: 
Author(s): 
Aiko Kume, Maria Shirley Herbas, Mototada Shichiri, Noriko Ishida & Hiroshi Suzuki
Reference: 
Parasitology Research, January 2016, Volume 115, Issue 1, pp 69-75

The current preventions of malaria are protection against mosquito bites and taking chemoprophylactic anti-malarial drugs.

Medical Treatment: 

Impact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei as well as in vitro CYP450 enzymatic activities in rat liver microsome

November 4, 2015 - 14:03 -- Open Access
Author(s): 
Shijie Wei, Hongyan Ji, Bei Yang, Liping Ma, Zhuchun Bei, Xiang Li, Hongwan Dang, Xiaoying Yang, Cheng Liu, Xiuli Wu, Jing Chen
Reference: 
Malaria Journal 2015, 14:432 (4 November 2015)

Co-administration of ART with CHR in ratio of 1:2 achieved a synergic anti-malarial effect partly because of the noncompetitive or uncompetitive inhibition of CHR of drug-metabolism enzymes, especially CYP3A which is closely related to the auto-induction of ART.

Medical Treatment: 

Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data

September 18, 2013 - 12:25 -- Open Access
Tags: 
Author(s): 
Allen EN, Chandler CI, Mandimika N, Pace C, Mehta U, Barnes KI
Reference: 
Malaria Journal 2013, 12:325 (16 September 2013)
MalariaWorld

It is critical to evaluate the safety of anti-malarial drugs being deployed in large, diverse populations.

Medical Treatment: 

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine

August 7, 2012 - 11:46 -- Kabogo Ndegwa
Author(s): 
Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V
Reference: 
Malaria Journal 2012, 11:259 (2 August 2012)

MalariaWorldAs a result of this work, CYP 2D6 and MAO-A have been implicated as the key enzymes associated with PQ metabolism, and metabolites previously identified as potentially playing a role in efficacy and haemolytic toxicity have been attributed to production via CYP 2D6 mediated pathways.

Medical Condition: 

Open Access | Molecular markers in Plasmodium falciparum linked to resistance to anti-malarial drugs in samples imported from Africa over an eight-year period (2002-2010): impact of the introduction of artemisinin combination therapy

April 4, 2012 - 13:38 -- Kabogo Ndegwa
Author(s): 
Amor A, Toro C, Fernandez-Martinez A, Baquero M, Benito A, Berzosa P
Reference: 
Malaria Journal 2012, 11:100 (30 March 2012)

MalariaWorldPharmacological pressure affects the resistance strains prevalence. As for SP, the disappearance of 436A and the decrease in 540 G suggest that these mutations are not fixed.

Medical Condition: 
Medical Treatment: 

Open Access | Development of a TaqMan Allelic Discrimination Assay for detection of Single Nucleotides Polymorphisms associated with anti-malarial drug resistance

January 24, 2012 - 13:29 -- Kabogo Ndegwa
Author(s): 
Kamau E, Alemayehu S, Feghali KC, Tolbert LS, Ogotu B, Ockenhouse CF
Reference: 
Malaria Journal 2012, 11:23 (20 January 2012)

MalariaWorldTaqMan Allelic Discrimination assay provides a good alternative tool in detection of SNPs associated with anti-malarial drug.

Medical Condition: 
Medical Treatment: 

Open Access | Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria

December 21, 2011 - 11:20 -- Kabogo Ndegwa
Author(s): 
Carlsson AM, Ngasala BE, Dahlstrom S, Membi C, Veiga IM, Rombo L, Abdullah S, Premji Z, Gil P, Bjorkman A, Martensson A
Reference: 
Malaria Journal 2011, 10:380 (20 December 2011)

MalariaWorldPCR analyses from multiple blood samples collected during the early treatment phase revealed a complex picture of parasite sub-populations.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa

June 16, 2011 - 07:48 -- Kabogo Ndegwa
Author(s): 
Slavic K, Krishna S, Derbyshire ET, Staines HM
Reference: 
Malaria Journal 2011, 10:165 (15 June 2011)

Glucose is the primary source of energy and a key substrate for most cells.

Medical Treatment: 

Open Access | Patterns of anti-malarial drug treatment among pregnant women in Uganda

June 7, 2011 - 07:44 -- Kabogo Ndegwa
Author(s): 
Sangare LR, Weiss NS, Brentlinger PE, Richardson BA, Staedke SG, Kiwuwa MS, Stergachis A
Reference: 
Malaria Journal 2011, 10:152 (6 June 2011)

Self-reported malaria was extremely common in this population and adherence to treatment guidelines for the management of malaria in pregnancy was poor.

Country: 
Medical Condition: 

Pages

Subscribe to RSS - anti-malarial drugs